Skinovation Pharmaceutical 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 10, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-30991
Entity Registrant Name	SKINOVATION PHARMACEUTICAL INC
Entity Central Index Key	0001118072
Entity Tax Identification Number	87-0458170
Entity Incorporation, State or Country Code	WY
Entity Address, Address Line One	2157 S. Lincoln Street
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84106
City Area Code	801
Local Phone Number	323-2395
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		708,000

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets
Cash	$ 552	$ 3,552
Total Current Assets	552	3,552
Total Assets	552	3,552
Current Liabilities
Accounts payable	10,500	6,000
Notes payable	234,021	230,521
Accrued interest	126,113	112,173
Total Current Liabilities	370,634	348,694
Total Liabilities	370,634	348,694
Stockholders' Deficit
Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding	708	708
Additional paid-in capital	25,148	25,148
Accumulated deficit	(395,938)	(370,998)
Total Stockholders' Deficit	(370,082)	(345,142)
Total Liabilities and Stockholders' Deficit	$ 552	$ 3,552

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	708,000	708,000
Common stock, shares outstanding	708,000	708,000

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
General and administrative	2,800	2,700	11,000	10,825
TOTAL EXPENSES	2,800	2,700	11,000	10,825
Loss from operations	(2,800)	(2,700)	(11,000)	(10,825)
OTHER EXPENSE
Interest expense	(4,680)	(4,448)	(13,940)	(12,942)
Total other income (expense)	(4,680)	(4,448)	(13,940)	(12,942)
LOSS BEFORE INCOME TAXES	(7,480)	(7,148)	(24,940)	(23,767)
INCOME TAX EXPENSE
NET LOSS	$ (7,480)	$ (7,148)	$ (24,940)	$ (23,767)
Basic and diluted net loss per share	$ (0.01)	$ (0.01)	$ (0.04)	$ (0.03)
Basic and diluted weighted average shares outstanding	708,000	708,000	708,000	708,000

Condensed Statements of Stockho

Condensed Statements of Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 708	$ 25,148	$ (340,041)	$ (314,185)
Beginning balance, shares at Dec. 31, 2019	708,000
Net loss			(9,602)	(9,602)
Ending balance, value at Mar. 31, 2020	$ 708	25,148	(349,643)	(323,787)
Ending balance, shares at Mar. 31, 2020	708,000
Beginning balance, value at Dec. 31, 2019	$ 708	25,148	(340,041)	(314,185)
Beginning balance, shares at Dec. 31, 2019	708,000
Net loss				(23,767)
Ending balance, value at Sep. 30, 2020	$ 708	25,148	(363,808)	(337,952)
Ending balance, shares at Sep. 30, 2020	708,000
Beginning balance, value at Mar. 31, 2020	$ 708	25,148	(349,643)	(323,787)
Beginning balance, shares at Mar. 31, 2020	708,000
Net loss			(7,017)	(7,017)
Ending balance, value at Jun. 30, 2020	$ 708	25,148	(356,660)	330,804
Ending balance, shares at Jun. 30, 2020	708,000
Net loss			(7,148)	(7,148)
Ending balance, value at Sep. 30, 2020	$ 708	25,148	(363,808)	(337,952)
Ending balance, shares at Sep. 30, 2020	708,000
Beginning balance, value at Dec. 31, 2020	$ 708	25,148	(370,998)	(345,142)
Beginning balance, shares at Dec. 31, 2020	708,000
Net loss			(10,010)	(10,010)
Ending balance, value at Mar. 31, 2021	$ 708	25,148	(381,008)	(355,152)
Ending balance, shares at Mar. 31, 2021	708,000
Beginning balance, value at Dec. 31, 2020	$ 708	25,148	(370,998)	(345,142)
Beginning balance, shares at Dec. 31, 2020	708,000
Net loss				(24,940)
Ending balance, value at Sep. 30, 2021	$ 708	25,148	(395,938)	(370,082)
Ending balance, shares at Sep. 30, 2021	708,000
Beginning balance, value at Mar. 31, 2021	$ 708	25,148	(381,008)	(355,152)
Beginning balance, shares at Mar. 31, 2021	708,000
Net loss			(7,450)	(7,450)
Ending balance, value at Jun. 30, 2021	$ 708	25,148	(388,458)	(362,602)
Ending balance, shares at Jun. 30, 2021	708,000
Net loss			(7,480)	(7,480)
Ending balance, value at Sep. 30, 2021	$ 708	$ 25,148	$ (395,938)	$ (370,082)
Ending balance, shares at Sep. 30, 2021	708,000

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash Flows from Operating Activities
Net loss	$ (24,940)	$ (23,767)
Changes in operating assets and liabilities:
Increase in accounts payable	4,500	3,300
Increase in accrued interest	13,940	12,942
Net cash used by operating activities	(6,500)	(7,525)
Cash Flows from Investing Activities
Net cash used by investing activities
Cash Flows from Financing Activities
Proceeds from notes payable	3,500	12,200
Net cash provided by financing activities	3,500	12,200
Increase (decrease) in cash	(3,000)	4,675
Cash and cash equivalents at beginning of period	3,552	77
Cash and cash equivalents at end of period	552	4,752
Supplemental Cash Flow Information:
Cash paid for interest
Cash paid for income taxes

NOTE 1 - CONDENSED FINANCIAL ST

NOTE 1 - CONDENSED FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NOTE 1 - CONDENSED FINANCIAL STATEMENTS	NOTE 1 - CONDENSED FINANCIAL STATEMENTS The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of and for the period ended September 30, 2021 and for all periods presented have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2020 audited financial statements as reported in its Form 10-K. The results of operations for the period ended September 30, 2021 are not necessarily indicative of the operating results for the full year ended December 31, 2021.

NOTE 2 - GOING CONCERN

NOTE 2 - GOING CONCERN	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NOTE 2 - GOING CONCERN	NOTE 2 - GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management's plan to acquire or merge with other operating companies. The COVID-19 pandemic could have an impact on our ability to obtain financing to fund our operations. The Company is unable to predict the ultimate impact at this time.

NOTE 3 - ACCOUNTS AND NOTES PAY

NOTE 3 - ACCOUNTS AND NOTES PAYABLE	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
NOTE 3 - ACCOUNTS AND NOTES PAYABLE	NOTE 3 - ACCOUNTS AND NOTES PAYABLE At September 30, 2021 and December 31, 2020, the Company had accounts payable of $ 10,500 6,000 234,021 230,521 3,500 12,200 8 Accrued interest on the notes was $ 126,113 112,173

NOTE 4 - SUBSEQUENT EVENTS

NOTE 4 - SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
NOTE 4 - SUBSEQUENT EVENTS	NOTE 4 - SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

NOTE 3 - ACCOUNTS AND NOTES P_2

NOTE 3 - ACCOUNTS AND NOTES PAYABLE (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Debt Disclosure [Abstract]
Accounts payable	$ 10,500		$ 6,000
Notes payable	234,021		230,521
Proceeds from notes payable	$ 3,500	$ 12,200
Interest rate on notes payable	8.00%	8.00%
Accrued interest on notes	$ 126,113		$ 112,173